Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • In a short-term perspective, the company has interesting fundamentals.
  • Merck & Co., Inc. accounts for 4.58 % of our USA Portfolio. A trade is currently open since 10/23/2019 with a purchase price of $ 81.01. Discover the other 19 stocks of the USA portfolio managed by the MarketScreener portfolio management team.
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • With an enterprise value anticipated at 4.36 times the sales for the current fiscal year, the company turns out to be overvalued.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
MERCK & CO., INC.-16.24%192 678
JOHNSON & JOHNSON-5.15%364 239
ROCHE HOLDING AG-6.18%276 926
PFIZER INC.-9.52%196 991
NOVARTIS AG-21.82%179 655
NOVO NORDISK A/S9.01%154 697
ABBVIE INC.-9.09%142 051
ASTRAZENECA PLC3.59%134 249
BRISTOL-MYERS SQUIBB COMPAN..-10.02%130 187
AMGEN INC.-10.24%126 732
ELI LILLY AND COMPANY-0.09%119 029
SANOFI-11.81%116 746
GLAXOSMITHKLINE PLC-25.58%85 559
JIANGSU HENGRUI MEDICINE CO..24.83%71 749
CHUGAI PHARMACEUTICAL CO., ..22.77%65 426
ALLERGAN PLC0.97%63 659
More Results
Financials (USD)
Sales 2020 48 111 M - -
Net income 2020 12 115 M - -
Net Debt 2020 17 081 M - -
P/E ratio 2020 16,2x
Yield 2020 3,17%
Capitalization 193 B 193 B -
EV / Sales 2020 4,36x
EV / Sales 2021 3,99x
Nbr of Employees 71 000
Free-Float 70,6%
Upcoming event on MERCK & CO., INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances -
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes